Drug combinations: Dangerous liaisons or great expectations? Editorial

Annals of Oncology

Volumn 10, Issue 4, 1999, Pages 375-376

  Ratain, M J ^a  

^a Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CREMOPHOR; DOXORUBICIN; PACLITAXEL; TAXANE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; EDITORIAL; HUMAN; POLYPHARMACY; PRIORITY JOURNAL;

EID: 0032953394     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008311912161     Document Type: Editorial

References (10)

1. Lazarou J. Pomeranz B.H. Corey P.R. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies JAMA 279 1998 1200 1205
2. Gianni L. Straneo M. Capri G. Optimal dose and sequence finding study of paclitaxel, by three-hour infusion combined with bolus doxorubicin in untreated metastatic breast cancer patients Proc Am Soc Clin Oncol 13 1994 A97
3. Gianni L. Munzone E. Capri G. Paclitaxel by three-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer. High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study J Clin Oncol 13 1995 2688 2699
4. Gehl J. Boesgaard M. Paaske T. Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic Ann Oncol 7 1996 687 693
5. Holmes F.A. Madden T. Newman R.A. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer J Clin Oncol 14 1996 2713 2721
6. Fisherman J.S. Cowan K.H. Noone M. Phase I-II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer J Clin Oncol 14 1996 774 782
7. Colombo T. Parisi I. Zucchetli M. Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin Ann Oncol 10 4 1999 391 395
8. Webster L.K. Cosson E.J. Stokes K.H. Millward M.J. Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice Br J Cancer 73 1996 522 524
9. Gianni L. Vigano L. Locatelli A. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer J Clin Oncol 15 1997 1906 1915
10. von Moltke L.L. Greenblall D.J. Schmider J. In vitro approaches to predicting drug interactions in vivo Biochem Pharmacol 55 1998 113 122